Mean (SD) data of patients with and without clinical significant macular oedema (CSMO)
| With CSMO (n=10) | Without CSMO (n=29) | |
| Age (years) | 33.7 (7.75) | 28.07 (5.67) |
| Duration of diabetes (years) | 22.8 (7.00) | 12.31 (7.22) |
| Duration of IIT (year) | 6.22 (2.33) | 5.95 (3.40) |
| HbA1C (%) | 6.94 (0.68) | 7.93 (1.04) |
| Functional tests | ||
| Visual acuity (LogMAR) | 0.07 (2.01) | –0.6 (0.17) |
| Mollon T | 2.1 (0.74) | 1.03 (0.19) |
| TCDS | 144.8 (23.34) | 132.23 (28.44) |
| Stereophotography | ||
| CSMO | 3.8 (0.42) | 1.0 (0.00) |
| Cystoid spaces | 1.5 (0.71) | 1.0 (0.00) |
| HE | 3.3 (1.42) | 1.07 (0.37) |
| Fluorescence angiography | ||
| FAZ size | 1.67 (1.00) | 1.86 (0.91) |
| FAZ outline | 3.0 (1.32) | 2.62 (1.11) |
| Capillary loss | 3.56 (0.88) | 2.79 (1.01) |
| Capillary dilatation | 3.11 (0.93) | 2.48 (1.02) |
| Leakage | 3.11 (1.05) | 1.0 (0.00) |
| Cystoid changes | 1.37 (1.06) | 1.0 (1.00) |
IIT= intensive insulin treatment; HbA1C = glycosylated haemoglobin; TCDS = total colour difference score; CSMO = clinically significant macular oedema; HE = hard exudates <1 DD from centre of macula; FAZ = foveal avascular zone.